Smith & Nephew plc (SNN)
| Market Cap | 14.14B |
| Revenue (ttm) | 5.94B |
| Net Income (ttm) | 491.00M |
| Shares Out | 874.63M |
| EPS (ttm) | 0.56 |
| PE Ratio | 28.79 |
| Forward PE | 15.43 |
| Dividend | $0.73 (2.20%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 1,003,937 |
| Open | 32.83 |
| Previous Close | 32.45 |
| Day's Range | 32.76 - 33.60 |
| 52-Week Range | 23.69 - 38.79 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 33.50 (+0.81%) |
| Earnings Date | Oct 30, 2025 |
About SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SNN stock is "Hold." The 12-month stock price target is $33.5, which is an increase of 0.81% from the latest price.
News
Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript
Smith & Nephew plc ( SNN) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Re...
Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release
Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis...
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound thera...
UFC® and Smith+Nephew announce multi-year extension of partnership
Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts or...
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the laun...
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant an...
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own...
Smith & Nephew: Doing Better And Still Offers Value
Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, an...
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference...
Top 2 Health Care Stocks You May Want To Dump In Q3
As of Aug. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint...
Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the l...
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will r...
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ev...
New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized ins...
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* co...
Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week
Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland
“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today anno...
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Cal...
Smith & Nephew: Underappreciated Recovery With Strategic Upside
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers...
Trump tariffs: these two European healthcare stocks face the highest US revenue exposure
Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are parti...
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Sur...
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopae...
New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Regi...